ES2703814T3 - Terapia génica para la enfermedad de Fabry - Google Patents
Terapia génica para la enfermedad de Fabry Download PDFInfo
- Publication number
- ES2703814T3 ES2703814T3 ES16721916T ES16721916T ES2703814T3 ES 2703814 T3 ES2703814 T3 ES 2703814T3 ES 16721916 T ES16721916 T ES 16721916T ES 16721916 T ES16721916 T ES 16721916T ES 2703814 T3 ES2703814 T3 ES 2703814T3
- Authority
- ES
- Spain
- Prior art keywords
- vector
- galactosidase
- nucleic acid
- sequence
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000024720 Fabry Disease Diseases 0.000 title claims description 31
- 238000001415 gene therapy Methods 0.000 title description 14
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 77
- 239000002773 nucleotide Substances 0.000 claims abstract description 75
- 108010030291 alpha-Galactosidase Proteins 0.000 claims abstract description 60
- 102000005840 alpha-Galactosidase Human genes 0.000 claims abstract description 60
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 52
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 48
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 48
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 48
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 27
- 108020004705 Codon Proteins 0.000 claims abstract description 25
- 210000004185 liver Anatomy 0.000 claims abstract description 22
- 239000013598 vector Substances 0.000 claims description 103
- 238000000034 method Methods 0.000 claims description 30
- 239000013607 AAV vector Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000005457 optimization Methods 0.000 abstract description 16
- 210000004027 cell Anatomy 0.000 description 43
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 28
- 241000125945 Protoparvovirus Species 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 15
- 210000000234 capsid Anatomy 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 238000012546 transfer Methods 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 8
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 7
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 7
- 241000702421 Dependoparvovirus Species 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 6
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 150000002339 glycosphingolipids Chemical class 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 4
- 241000701945 Parvoviridae Species 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 238000000635 electron micrograph Methods 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- YUDPTGPSBJVHCN-CHUNWDLHSA-N 4-methylumbelliferyl alpha-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-CHUNWDLHSA-N 0.000 description 2
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 241000121250 Parvovirinae Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101710150114 Protein rep Proteins 0.000 description 2
- 101710152114 Replication protein Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000013609 scAAV vector Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 1
- 241000425548 Adeno-associated virus 3A Species 0.000 description 1
- 241000958487 Adeno-associated virus 3B Species 0.000 description 1
- 102100026277 Alpha-galactosidase A Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000121256 Densovirinae Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100028993 Hippocalcin-like protein 1 Human genes 0.000 description 1
- 101000870662 Homo sapiens ATP-dependent RNA helicase DDX3X Proteins 0.000 description 1
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 description 1
- 101000838883 Homo sapiens Hippocalcin-like protein 1 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010049936 agalsidase alfa Proteins 0.000 description 1
- 229960001239 agalsidase alfa Drugs 0.000 description 1
- 108010056760 agalsidase beta Proteins 0.000 description 1
- 229960004470 agalsidase beta Drugs 0.000 description 1
- -1 alpha-galactosyl moieties Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002641 enzyme replacement therapy Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 238000001239 high-resolution electron microscopy Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002812 neutral glycosphingolipids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000013608 rAAV vector Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Environmental Sciences (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1508025.2A GB201508025D0 (en) | 2015-05-11 | 2015-05-11 | Fabry disease gene therapy |
| PCT/GB2016/051328 WO2016181122A1 (en) | 2015-05-11 | 2016-05-10 | Fabry disease gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2703814T3 true ES2703814T3 (es) | 2019-03-12 |
Family
ID=53489437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16721916T Active ES2703814T3 (es) | 2015-05-11 | 2016-05-10 | Terapia génica para la enfermedad de Fabry |
Country Status (17)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| CN114606267A (zh) | 2015-09-28 | 2022-06-10 | 北卡罗来纳-查佩尔山大学 | 逃避抗体的病毒载体的方法和组合物 |
| WO2017201328A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE |
| EA202092362A1 (ru) | 2018-04-03 | 2021-01-11 | Страйдбайо, Инк. | Вирусные векторы для нацеливания на ткани глаза |
| EP3774852A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Antibody-evading virus vectors |
| WO2019210187A1 (en) * | 2018-04-26 | 2019-10-31 | The University Of North Carolina At Chapel Hill | Methods and compositions for treatment of hemophilia |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| KR20210049129A (ko) * | 2018-08-20 | 2021-05-04 | 유씨엘 비즈니스 리미티드 | 인자 ix를 코딩하는 뉴클레오타이드 |
| CA3115944A1 (en) | 2018-10-10 | 2020-04-16 | Amicus Therapeutics, Inc. | Disulfide bond stabilized polypeptide compositions and methods of use |
| BR112021018776A2 (pt) | 2019-03-21 | 2021-11-30 | Stridebio Inc | Vetores de vírus adenoassociado recombinante |
| CA3147055A1 (en) * | 2019-08-07 | 2021-02-11 | Elfrida Benjamin | Methods of treating fabry disease in patients having a mutation in the gla gene |
| CN114787180A (zh) | 2019-10-17 | 2022-07-22 | 斯特里迪比奥公司 | 用于治疗c型尼曼-匹克病的腺相关病毒载体 |
| WO2021084277A2 (en) | 2019-11-01 | 2021-05-06 | Freeline Therapeutics Limited | Transcription regulatory elements |
| WO2021183895A1 (en) * | 2020-03-13 | 2021-09-16 | Biomarin Pharmaceutical Inc. | Treatment of fabry disease with aav gene therapy vectors |
| MX2022013411A (es) * | 2020-04-27 | 2022-11-14 | 4D Molecular Therapeutics Inc | Genes gla con codones optimizados y usos de los mismos. |
| KR20230002594A (ko) * | 2020-04-29 | 2023-01-05 | 살리오젠 테라퓨틱스 인코포레이티드 | 가족성 고콜레스테롤혈증 및 상승된 저밀도 지단백질 콜레스테롤의 치료를 위한 조성물 및 방법 |
| US12104163B2 (en) | 2020-08-19 | 2024-10-01 | Sarepta Therapeutics, Inc. | Adeno-associated virus vectors for treatment of Rett syndrome |
| CN114829606B (zh) * | 2020-11-16 | 2024-03-19 | 北京三诺佳邑生物技术有限责任公司 | 一种增强肝靶向性的重组腺相关病毒及其用途 |
| CN114507692B (zh) * | 2020-11-16 | 2024-07-12 | 舒泰神（北京）生物制药股份有限公司 | 用于治疗法布里病的腺相关病毒载体及其用途 |
| CN117858713A (zh) * | 2021-04-20 | 2024-04-09 | 步行鱼治疗学股份有限公司 | 工程改造基于b细胞的蛋白质工厂以治疗严重疾病 |
| GB202205514D0 (en) | 2022-04-13 | 2022-05-25 | Freeline Therapeutics Ltd | Mechanical lysis |
| CN114672501B (zh) * | 2022-05-27 | 2022-08-23 | 珠海丽凡达生物技术有限公司 | 一种mRNA、药物组合物及其应用 |
| WO2024044697A2 (en) * | 2022-08-24 | 2024-02-29 | Walking Fish Therapeutics, Inc. | Compositions and methods for treatment of fabry disease |
| CN121002183A (zh) * | 2023-04-17 | 2025-11-21 | 杭州复因生物科技有限公司 | 用于基因治疗的组合物和方法 |
| CN116656704B (zh) * | 2023-06-01 | 2024-11-05 | 华东理工大学 | 用于治疗法布里病的转基因表达盒 |
| CN116622750B (zh) * | 2023-06-01 | 2024-05-31 | 上海勉亦生物科技有限公司 | 优化的人法布里转基因表达盒及其用途 |
| WO2025087695A1 (en) | 2023-10-23 | 2025-05-01 | Ascend Advanced Therapies Ltd | Method for producing recombinant adeno-associated virus particles |
Family Cites Families (189)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6846968B1 (en) | 1988-02-26 | 2005-01-25 | Large Scale Biology Corporation | Production of lysosomal enzymes in plants by transient expression |
| US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
| AU719950B2 (en) | 1995-06-07 | 2000-05-18 | Yale University | Oral delivery of adeno-associated viral vectors |
| US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| AU762400B2 (en) | 1996-09-13 | 2003-06-26 | Shire Human Genetic Therapies, Inc. | Therapy for alpha-galactosidase a deficiency |
| DK1538202T3 (en) | 1996-09-13 | 2014-03-24 | Shire Human Genetic Therapies | PREPARATION OF HUMANT ALPHA-GALACTOSIDASE A |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| US20020082224A1 (en) | 1997-01-14 | 2002-06-27 | Douglas J. Jolly | Non-immunogenic prodrugs and selectable markers for use in gene therapy |
| GB9708526D0 (en) | 1997-04-25 | 1997-06-18 | Royal Free Hosp School Med | Eukaryotic gene expression cassette and uses thereof |
| US6210666B1 (en) | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
| EP1658857A1 (en) | 1997-10-29 | 2006-05-24 | Genzyme Corporation | Compositions and methods for treating lysosomal storage disease |
| WO2000009153A1 (en) | 1997-10-29 | 2000-02-24 | Genzyme Corporation | Compositions and methods for treating lysosomal storage disease |
| US6607879B1 (en) | 1998-02-09 | 2003-08-19 | Incyte Corporation | Compositions for the detection of blood cell and immunological response gene expression |
| WO1999041399A1 (en) | 1998-02-17 | 1999-08-19 | Genzyme Corporation | Methods for purified aav vector production |
| WO1999057296A1 (en) | 1998-05-01 | 1999-11-11 | Genzyme Corporation | Partially deleted adenoviral vectors |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US20020065236A1 (en) | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
| US20090148906A1 (en) | 1998-09-29 | 2009-06-11 | Shire Human Genetic Therapies, Inc. A Delaware Corporation | Optimized messenger rna |
| AU2004242550B2 (en) | 1999-03-11 | 2008-04-03 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-Galactosidase A deficiency |
| GB9909066D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| US7927587B2 (en) | 1999-08-05 | 2011-04-19 | Regents Of The University Of Minnesota | MAPC administration for the treatment of lysosomal storage disorders |
| WO2002064799A2 (en) | 1999-09-28 | 2002-08-22 | Transkaryotic Therapies, Inc. | Optimized messenger rna |
| EP2275559A3 (en) | 1999-09-28 | 2011-03-23 | Shire Human Genetic Therapies, Inc. | Optimized messenger RNA |
| CA2388151C (en) | 1999-11-05 | 2010-01-12 | Jena Bioscience Gmbh | Protein expression systems for non-pathogenic kinetoplastidae |
| ES2284545T3 (es) | 1999-11-16 | 2007-11-16 | Genzyme Corporation | Vectores y transgenes con elementos reguladores para la administracion de genes del higado. |
| WO2001049830A2 (en) | 1999-12-30 | 2001-07-12 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
| WO2001060377A2 (en) | 2000-02-17 | 2001-08-23 | Genzyme Corporation | Methods for treatment of lysosomal storage diseases using biphosphonates |
| CA2400634A1 (en) | 2000-02-17 | 2001-08-23 | Chester Li | Genetic modification of the lung as a portal for gene delivery |
| US20020081654A1 (en) | 2000-04-07 | 2002-06-27 | Sandrin Mauro Sergio | Targeting hydrolase enzymes |
| US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20020014242A1 (en) | 2000-07-31 | 2002-02-07 | Abraham Scaria | Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products |
| ES2252293T3 (es) | 2000-09-18 | 2006-05-16 | Genzyme Corporation | Vectores de expresion que contienene promotores hibridos de ubiquitina. |
| EP1624067A3 (en) | 2000-09-18 | 2006-03-15 | Genzyme Corporation | Expression vectors containing hybrid ubiquitin promoters |
| DK1325138T3 (da) | 2000-10-11 | 2013-10-21 | Shire Human Genetic Therapies | Optimeret messenger rna |
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| EP1390490B1 (en) | 2001-05-24 | 2009-04-15 | Genzyme Corporation | Muscle-specific expression vectors |
| JP4742191B2 (ja) | 2001-06-14 | 2011-08-10 | 独立行政法人産業技術総合研究所 | 糖蛋白質およびその製造方法 |
| US7063962B2 (en) | 2001-07-20 | 2006-06-20 | Novozymes A/S | DNA sequences for regulating transcription |
| US6749851B2 (en) | 2001-08-31 | 2004-06-15 | Clearant, Inc. | Methods for sterilizing preparations of digestive enzymes |
| US6783968B2 (en) | 2001-09-24 | 2004-08-31 | Clearant, Inc. | Methods for sterilizing preparations of glycosidases |
| US20030064000A1 (en) | 2001-09-24 | 2003-04-03 | Wilson Burgess | Methods of sterilizing biological mixtures using stabilizer mixtures |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| EP1336411A1 (en) | 2002-02-14 | 2003-08-20 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases |
| WO2003072035A2 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1503788B1 (en) | 2002-04-25 | 2011-06-29 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-galactosidase a deficiency |
| US20030225260A1 (en) | 2002-04-30 | 2003-12-04 | Snyder Richard O. | Production of recombinant AAV virions |
| AU2003220115A1 (en) | 2002-05-20 | 2003-12-12 | Board Of Regents, The University Of Texas System | Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues |
| WO2003101202A1 (en) | 2002-05-31 | 2003-12-11 | Osiris Therapeutics, Inc. | Intraperitoneal delivery of genetically engineered mesenchymal stem cells |
| US20030224477A1 (en) | 2002-05-31 | 2003-12-04 | Heartlein Michael W. | Optimized promoter constructs |
| CA2503390A1 (en) | 2002-11-01 | 2004-05-21 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004047728A2 (en) | 2002-11-26 | 2004-06-10 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| ES2371913T3 (es) | 2003-01-22 | 2012-01-11 | Duke University | Constructos mejorados para expresar polipéptidos lisosomales. |
| ES2686775T3 (es) | 2003-01-31 | 2018-10-19 | Mount Sinai School Of Medicine Of New York University | Terapia de combinación para tratar trastornos de deficiencia de proteínas |
| US7446098B2 (en) | 2003-02-18 | 2008-11-04 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiencies |
| EP1606313A2 (en) | 2003-03-19 | 2005-12-21 | Isogenis, Inc. | Specific inhibition of allograft rejection |
| US7951557B2 (en) | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| US20100196345A1 (en) | 2003-04-27 | 2010-08-05 | Protalix | Production of high mannose proteins in plant culture |
| EP3513814A1 (en) | 2003-05-01 | 2019-07-24 | Genzyme Corporation | Gene therapy for neurometabolic disorders |
| JP2006525371A (ja) | 2003-05-05 | 2006-11-09 | ジェンザイム コーポレイション | 免疫応答を減少させる方法 |
| US7423135B2 (en) | 2003-06-24 | 2008-09-09 | Genzyme Corporation | β-actin and rpS21 promoters and uses thereof |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CA2549404A1 (en) | 2003-12-04 | 2005-06-23 | Regents Of The University Of Minnesota | Compositions and methods for the treatment of lysosomal storage disorders |
| US20060029656A1 (en) | 2004-02-03 | 2006-02-09 | Biodelivery Sciences International, Inc. | Replacement enzyme cochleates |
| AU2005211775B2 (en) | 2004-02-06 | 2009-10-08 | Biomarin Pharmaceutical Inc. | Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
| US20050208090A1 (en) | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| WO2006007560A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pennsylvania | Targeted protein replacement for the treatment of lysosomal storage disorders |
| EP1828390B1 (en) | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| PL3058959T3 (pl) | 2005-05-02 | 2019-07-31 | Genzyme Corporation | Terapia genowa dla zaburzeń neurometabolicznych |
| US8500720B2 (en) | 2005-05-09 | 2013-08-06 | Medtronic, Inc | Method and apparatus for treatment of cardiac disorders |
| CN101278052A (zh) | 2005-07-18 | 2008-10-01 | 普罗塔里克斯有限公司 | 生物活性大分子的粘膜或肠给药 |
| EP2502491B1 (en) | 2005-10-31 | 2017-05-10 | Velico Medical, Inc. | Novel alpha-galactosidases |
| JP4368925B2 (ja) | 2005-11-18 | 2009-11-18 | 財団法人 東京都医学研究機構 | 基質特異性を変換した新規高機能酵素 |
| AR059089A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| US7867484B2 (en) | 2006-01-27 | 2011-01-11 | University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
| EP3456331B1 (en) | 2006-02-08 | 2021-05-26 | Genzyme Corporation | Gene therapy for niemann-pick disease type a |
| PT1988823T (pt) | 2006-02-09 | 2018-11-22 | Genzyme Corp | Administração intraventricular lenta |
| DK2533050T6 (da) | 2006-05-16 | 2015-09-21 | Amicus Therapeutics Inc | Behandlingsmuligheder ved Fabrys sygdom |
| EP2121005A1 (en) | 2006-12-21 | 2009-11-25 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Treatment of fabry disease |
| ES2417146T3 (es) | 2007-01-18 | 2013-08-06 | Genzyme Corporation | Oligosacáridos que comprenden un grupo aminoxi y conjugados de los mismos |
| CA2584494A1 (en) | 2007-03-27 | 2008-09-27 | Jeffrey A. Medin | Vector encoding therapeutic polypeptide and safety elements to clear transduced cells |
| US20100113517A1 (en) | 2007-03-30 | 2010-05-06 | Amicus Therapeutics, Inc. | Method for the treatment of fabry disease using pharmacological chaperones |
| US9056101B2 (en) | 2007-04-26 | 2015-06-16 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| ES2635726T3 (es) | 2007-06-06 | 2017-10-04 | Genzyme Corporation | Terapia génica para enfermedades de almacenamiento lisosómico |
| US20100291060A1 (en) | 2007-08-29 | 2010-11-18 | Shire Human Genetic Therapies, Inc | Subcutaneous administration of alpha-galactosidase a |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| US20100317690A1 (en) | 2007-11-21 | 2010-12-16 | Summit Corporation Plc | Treatment of protein folding disorders |
| AU2009209408B2 (en) | 2008-01-29 | 2015-06-11 | Beacon Therapeutics Limited | Recombinant virus production using mammalian cells in suspension |
| HUE042882T2 (hu) | 2008-02-12 | 2019-07-29 | Amicus Therapeutics Inc | Eljárás betegségek farmakológiai chaperonnal történõ kezelésére adott válasz elõrejelzésére |
| US8568709B2 (en) | 2008-03-20 | 2013-10-29 | University Health Network | Thymidylate kinase fusions and uses thereof |
| US8632764B2 (en) | 2008-04-30 | 2014-01-21 | University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
| ES2385735T3 (es) | 2008-06-26 | 2012-07-31 | Orphazyme Aps | Uso de Hsp70 como regulador de la actividad enzimática |
| EP2323652A2 (en) | 2008-08-06 | 2011-05-25 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| HUE044381T2 (hu) | 2008-12-16 | 2019-10-28 | Genzyme Corp | Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállításához |
| EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
| WO2011019980A1 (en) | 2009-08-14 | 2011-02-17 | University Of Miami | Novel role of alpha-galactosidase activity as a biomarker in kidney disease |
| CN102712914A (zh) | 2009-09-29 | 2012-10-03 | 根特大学 | 水解甘露糖-1-磷酸-6-甘露糖连接为磷酸-6-甘露糖 |
| JP2013506697A (ja) | 2009-10-06 | 2013-02-28 | アンジオケム インコーポレーテッド | 治療薬を輸送するための組成物と方法 |
| HRP20161223T1 (hr) | 2009-10-27 | 2016-11-18 | Erytech Pharma | Pripravak za induciranje specifične imune tolerancije |
| WO2011057243A2 (en) | 2009-11-09 | 2011-05-12 | University Of Central Florida Research Foundation, Inc. | Administration of plant expressed oral tolerance agents |
| WO2011061736A1 (en) | 2009-11-17 | 2011-05-26 | Protalix Ltd. | Alkaline alpha galactosidase for the treatment of fabry disease |
| US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| WO2011066352A1 (en) | 2009-11-27 | 2011-06-03 | Genzyme Corporation | An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase |
| US9169494B2 (en) | 2010-01-12 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| CN102933707B (zh) | 2010-03-02 | 2015-09-30 | 普罗塔里克斯有限公司 | 稳定的α-半乳糖苷酶及其用途 |
| KR20130010121A (ko) | 2010-03-23 | 2013-01-25 | 인트렉손 코포레이션 | 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도 |
| US8809282B2 (en) | 2010-05-06 | 2014-08-19 | Duke University | Method of reducing titers of antibodies specific for a therapeutic agent |
| WO2011163648A1 (en) | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| US20130224757A1 (en) | 2010-08-19 | 2013-08-29 | Novozymes A/S | Induced sporulation screening method |
| US9347050B2 (en) | 2010-09-29 | 2016-05-24 | Oxyrane Uk Limited | Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins |
| WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
| RS60129B1 (sr) | 2011-01-20 | 2020-05-29 | Protalix Ltd | Kompozicije alfa-galaktozidaze |
| CN107088225A (zh) | 2011-03-11 | 2017-08-25 | 阿米库斯治疗学公司 | 治疗法布里病的给药方案 |
| PT2691529T (pt) | 2011-03-31 | 2019-09-27 | Univ Iowa Res Found | Partícula de aav2 que compreende uma proteína do capsídeo de aav2 e um vetor que compreende um ácido nucleico que codifica uma tripeptidil peptidase 1 (tpp1) para utilização no tratamento da lipofuscinose ceroide infantil tardia (lincl) num mamífero não roedor por injeção intraventricular ou entrega icv |
| US20120283290A1 (en) | 2011-05-06 | 2012-11-08 | Amicus Therapeutics Inc. | Quantitation of gl3 in urine |
| EP2717893B1 (en) | 2011-06-08 | 2019-05-08 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| KR102076585B1 (ko) | 2011-12-22 | 2020-02-12 | 센토제너 아이피 게엠베하 | 리소좀 효소를 재배열하는 능력을 갖는 화합물 및 암브록솔 및/또는 암브록솔의 유도체의 조합물 |
| CN104428009A (zh) | 2012-02-07 | 2015-03-18 | 全球生物疗法美国有限公司 | 核酸输送的区室化方法及其组合物和应用 |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| CA2868034C (en) | 2012-03-29 | 2021-07-27 | Shire Human Genetic Therapies, Inc. | Ionizable cationic lipids |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| AU2013243949A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| EP2839001B1 (en) | 2012-04-18 | 2017-09-06 | VIB vzw | Means and methods for generating improved proteins |
| CA2874316A1 (en) | 2012-05-03 | 2013-11-07 | Indiana University Research And Technology Corporation | Hydrodynamic methods for delivering fluids to kidney tissues and related materials and methods |
| WO2013181454A1 (en) | 2012-05-30 | 2013-12-05 | Biostrategies LC | Plant lectins as carriers of associated drug substances into animal and human cells |
| US10648001B2 (en) | 2012-07-11 | 2020-05-12 | Sangamo Therapeutics, Inc. | Method of treating mucopolysaccharidosis type I or II |
| AU2013289206B2 (en) | 2012-07-11 | 2018-08-09 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of lysosomal storage diseases |
| US9694056B2 (en) | 2012-07-17 | 2017-07-04 | Amicus Therapeutics, Inc. | α-galactosidase A and 1-deoxygalactonojirimycin co-formulation |
| GB201213117D0 (en) | 2012-07-24 | 2012-09-05 | Ucl Business Plc | Transgene expression |
| WO2014017915A2 (en) | 2012-07-27 | 2014-01-30 | Universiteit Utrecht Holding B.V. | Urea and guanidinium derivatives of iminosugars |
| WO2014022515A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| US10138474B2 (en) | 2012-08-17 | 2018-11-27 | Research Foundation Of The City University Of New York | Scavenger receptor uptake for fabry disease enzyme replacement therapy |
| ES2968649T3 (es) | 2012-12-07 | 2024-05-13 | Translate Bio Inc | Nanopartículas lipídicas para la administración de ARNm en los pulmones |
| WO2014120900A1 (en) | 2013-01-31 | 2014-08-07 | Icahn School Of Medicine At Mount Sinai | Enhanced therapeutic regimens for treating fabry disease |
| JP2016514152A (ja) | 2013-03-13 | 2016-05-19 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | アデノ随伴ウイルスベクターおよびその使用の方法 |
| CN105026411A (zh) | 2013-03-14 | 2015-11-04 | 夏尔人类遗传性治疗公司 | 含4’-硫代修饰的核苷酸的核糖核酸及相关方法 |
| WO2014143932A1 (en) | 2013-03-15 | 2014-09-18 | The University Of North Carolina At Chapel Hill | Synthetic adeno-associated virus inverted terminal repeats |
| ES2804594T3 (es) | 2013-03-15 | 2021-02-08 | Amicus Therapeutics Inc | Reticuladores químicos |
| US9719106B2 (en) | 2013-04-29 | 2017-08-01 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof |
| EP3622821A1 (en) | 2013-05-15 | 2020-03-18 | Regents of the University of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
| EP3008191A2 (en) | 2013-06-13 | 2016-04-20 | Shire Human Genetic Therapies, Inc. | Messenger rna based viral production |
| US20140377246A1 (en) | 2013-06-19 | 2014-12-25 | Carol Ann Foundation and International Morquio Organization | Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme |
| EP3024497B1 (en) | 2013-07-26 | 2021-01-13 | University of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| ME03590B (me) | 2013-08-13 | 2020-07-20 | Univ Northwestern | Čestice konjugovane peptidom |
| TW202332774A (zh) | 2013-10-23 | 2023-08-16 | 美商健臻公司 | 重組醣蛋白及其用途 |
| EP3060669B1 (en) | 2013-10-24 | 2024-12-11 | uniQure IP B.V. | Aav-5 pseudotyped vector for gene therapy for neurological diseases |
| DK3068869T3 (da) | 2013-11-15 | 2020-09-07 | Univ Pennsylvania | Sammensætninger til suppression af inhibitorformation mod faktor VIII i patienter med hæmofili A |
| SG10201804952QA (en) | 2013-12-11 | 2018-07-30 | Genzyme Corp | Glucosylceramide synthase inhibitors |
| KR102128145B1 (ko) | 2013-12-23 | 2020-06-30 | 비씨엔 펩티드즈, 에스.에이. | 리소좀 축적 질환 또는 당원병의 치료에서 사용하기 위한 엑소사이토시스 활성화 화합물로서의 비칼루타미드 유사체 또는 （ｓ）-비칼루타미드 |
| JP2017510623A (ja) | 2014-02-04 | 2017-04-13 | ニューヨーク ユニバーシティ | リソソーム蓄積症の診断および治療のためのプログラニュリン（ｐｇｒｎ）およびその誘導体 |
| IL248102B (en) | 2014-05-02 | 2022-07-01 | Genzyme Corp | aav vectors for gene therapy of the central nervous system and retina |
| JP6652334B2 (ja) | 2014-05-31 | 2020-02-19 | Ｊｃｒファーマ株式会社 | ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地 |
| IL292574A (en) | 2014-09-07 | 2022-06-01 | Selecta Biosciences Inc | Methods and compositions for attenuating anti-viral transfer vector immune responses |
| JP2017534640A (ja) | 2014-11-10 | 2017-11-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルファ−ｌ−イズロニダーゼ、イズロン酸−２−スルファターゼおよびアルファガラクトシダーゼａの治療用組成物ならびにそれらの使用方法 |
| TW201632626A (zh) | 2014-11-21 | 2016-09-16 | 臺北榮民總醫院 | 製備誘導性多功能幹細胞之方法 |
| EP3230458B1 (en) | 2014-12-12 | 2020-02-19 | CureVac AG | Artificial nucleic acid molecules for improved protein expression |
| US10889834B2 (en) | 2014-12-15 | 2021-01-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing targeted transgene integration |
| EP3237621B1 (en) | 2014-12-22 | 2023-04-19 | Codexis, Inc. | Human alpha-galactosidase variants |
| CA2966092A1 (en) | 2014-12-30 | 2016-07-07 | Curevac Ag | Artificial nucleic acid molecules |
| WO2016115382A1 (en) | 2015-01-14 | 2016-07-21 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeted gene transfer |
| WO2016118780A1 (en) | 2015-01-21 | 2016-07-28 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| KR102863734B1 (ko) | 2015-02-10 | 2025-09-25 | 젠자임 코포레이션 | 선조체 및 피질로의 바이러스 입자의 향상된 전달 |
| KR20170116159A (ko) | 2015-02-19 | 2017-10-18 | 다니스코 유에스 인크. | 향상된 단백질 발현 |
| WO2016134338A1 (en) | 2015-02-19 | 2016-08-25 | University Of Florida Research Foundation, Inc. | Recombinant aav vectors for gene therapy of human hematopoietic disorders |
| JP6936150B2 (ja) | 2015-03-17 | 2021-09-15 | エレヴァ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングｅｌｅｖａ ＧｍｂＨ | グリコシル化リソソームタンパク質、その製造方法および使用 |
| EP3277819B1 (en) | 2015-03-24 | 2021-03-03 | The Regents of The University of California | Adeno-associated virus variants and methods of use thereof |
| WO2016154313A1 (en) | 2015-03-24 | 2016-09-29 | Zywie, Llc | High drug loading liquid oral pharmaceutical compositions |
| US9981021B1 (en) | 2015-04-09 | 2018-05-29 | Kinetiq, Inc. | Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof |
| CA3019315A1 (en) | 2015-04-23 | 2016-10-27 | University Of Massachusetts | Modulation of aav vector transgene expression |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| RU2751952C2 (ru) | 2015-05-15 | 2021-07-21 | Реджентс Оф Зэ Юниверсити Оф Миннесота | Вектор на основе аденоассоциированного вируса для терапевтической доставки в центральную нервную систему |
| EP4219532A3 (en) | 2015-06-05 | 2023-08-16 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for transient gene therapy with enhanced stability |
| JP2018519827A (ja) | 2015-07-01 | 2018-07-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 逆配向のヒトユビキチンｃプロモーターを含むレトロウイルスベクター |
| WO2017024137A1 (en) | 2015-08-04 | 2017-02-09 | New York University | Progranulin (pgrn) fragments and derivatives for treatment or alleviation of lysosomal storage diseases |
| US20170051267A1 (en) | 2015-08-20 | 2017-02-23 | Research Foundation Of The City University Of New York | Novel alpha-galactosidase a derivatives |
| WO2017049161A1 (en) | 2015-09-18 | 2017-03-23 | Duke University | ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER |
| US20190112588A1 (en) | 2015-12-08 | 2019-04-18 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| DK3390429T3 (da) | 2015-12-14 | 2025-08-25 | Univ North Carolina Chapel Hill | Modificerede kapsid-proteiner til forbedret afgivelse af parvovirus-vektorer |
| GB201522243D0 (en) | 2015-12-16 | 2016-01-27 | Ucl Business Plc | Treatment |
| JP6993339B2 (ja) | 2015-12-23 | 2022-02-21 | ダニスコ・ユーエス・インク | タンパク質産生の強化およびその方法 |
| CA3009799A1 (en) | 2016-01-04 | 2017-07-13 | Cour Pharmaceuticals Development Company Inc. | Particles encapsulating fusion proteins containing linked epitopes |
| WO2017122093A1 (en) | 2016-01-11 | 2017-07-20 | Medgenics Medical Israel Ltd. | Compositions and methods for treatment of central nervous system diseases |
| AR107483A1 (es) | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| SI3411484T1 (sl) | 2016-02-05 | 2023-12-29 | Emory University | Injiciranje enojnega ali samokomplementarnega adeno-povezanega virusa 9 v cerebrospinalno tekočino |
| EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| US20180126003A1 (en) | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
-
2015
- 2015-05-11 GB GBGB1508025.2A patent/GB201508025D0/en not_active Ceased
-
2016
- 2016-05-10 PL PL16721916T patent/PL3244931T3/pl unknown
- 2016-05-10 AU AU2016261453A patent/AU2016261453C1/en not_active Ceased
- 2016-05-10 ES ES16721916T patent/ES2703814T3/es active Active
- 2016-05-10 DK DK16721916.1T patent/DK3244931T3/en active
- 2016-05-10 CN CN201680027116.1A patent/CN107980063B/zh not_active Expired - Fee Related
- 2016-05-10 WO PCT/GB2016/051328 patent/WO2016181122A1/en not_active Ceased
- 2016-05-10 PT PT16721916T patent/PT3244931T/pt unknown
- 2016-05-10 HR HRP20190165TT patent/HRP20190165T1/hr unknown
- 2016-05-10 EP EP16721916.1A patent/EP3244931B1/en active Active
- 2016-05-10 KR KR1020177035510A patent/KR20180012772A/ko not_active Ceased
- 2016-05-10 TR TR2018/20102T patent/TR201820102T4/tr unknown
- 2016-05-10 JP JP2017558727A patent/JP6688812B2/ja not_active Expired - Fee Related
- 2016-05-10 CA CA2985935A patent/CA2985935C/en active Active
- 2016-05-10 EP EP18196625.0A patent/EP3470088A1/en active Pending
- 2016-05-10 US US15/573,203 patent/US11103596B2/en active Active
- 2016-05-10 LT LTEP16721916.1T patent/LT3244931T/lt unknown
- 2016-05-11 TW TW105114579A patent/TW201706412A/zh unknown
-
2021
- 2021-07-27 US US17/386,063 patent/US12370268B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107980063B (zh) | 2021-12-10 |
| US20180110878A1 (en) | 2018-04-26 |
| HRP20190165T1 (hr) | 2019-04-05 |
| JP6688812B2 (ja) | 2020-04-28 |
| AU2016261453B2 (en) | 2019-03-28 |
| CN107980063A (zh) | 2018-05-01 |
| KR20180012772A (ko) | 2018-02-06 |
| DK3244931T3 (en) | 2019-02-11 |
| EP3470088A1 (en) | 2019-04-17 |
| AU2016261453A1 (en) | 2017-11-23 |
| PT3244931T (pt) | 2019-01-21 |
| EP3244931A1 (en) | 2017-11-22 |
| PL3244931T3 (pl) | 2019-04-30 |
| US11103596B2 (en) | 2021-08-31 |
| WO2016181122A1 (en) | 2016-11-17 |
| TW201706412A (zh) | 2017-02-16 |
| CA2985935A1 (en) | 2016-11-17 |
| AU2016261453C1 (en) | 2019-09-12 |
| US12370268B2 (en) | 2025-07-29 |
| LT3244931T (lt) | 2019-02-11 |
| TR201820102T4 (tr) | 2019-01-21 |
| GB201508025D0 (en) | 2015-06-24 |
| EP3244931B1 (en) | 2018-10-24 |
| JP2018520646A (ja) | 2018-08-02 |
| US20220016263A1 (en) | 2022-01-20 |
| CA2985935C (en) | 2022-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2703814T3 (es) | Terapia génica para la enfermedad de Fabry | |
| US20250236887A1 (en) | Adeno-associated virus (aav) systems for treatment of genetic hearing loss | |
| CN110520536B (zh) | 用于穿过维管结构的基因转移的方法和组合物 | |
| ES2989774T3 (es) | Factor IX modificado, y composiciones, métodos y utilizaciones para la transferencia génica a células, órganos y tejidos | |
| US10413598B2 (en) | Factor IX gene therapy | |
| US11142775B2 (en) | Bocaparvovirus small noncoding RNA and uses thereof | |
| CN110997923A (zh) | 腺相关病毒载体递送肌肉特异性微肌营养不良蛋白以治疗肌营养不良症 | |
| JP2019506445A (ja) | パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質 | |
| KR20160026841A (ko) | 스터퍼/필러 폴리누클레오티드 서열을 포함하는 벡터 및 사용 방법 | |
| ES2862164T3 (es) | Genoterapia de la enfermedad de Wilson | |
| CN117897492A (zh) | 用于肌肉和cns中的基因表达的杂合启动子 | |
| US20230151390A1 (en) | Vectors for the treatment of acid ceramidase deficiency | |
| JP2024515902A (ja) | 組織向性が改善されたアデノ随伴ウイルスベクターカプシド |